Alphatec Holdings, Inc. (NASDAQ:ATEC) Shares Acquired by American Century Companies Inc.

American Century Companies Inc. boosted its stake in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 36.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,989,057 shares of the medical technology company's stock after acquiring an additional 1,334,780 shares during the period. American Century Companies Inc. owned about 3.52% of Alphatec worth $45,800,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Semanteon Capital Management LP acquired a new stake in shares of Alphatec in the fourth quarter valued at approximately $302,000. Intech Investment Management LLC raised its position in Alphatec by 14.7% in the 4th quarter. Intech Investment Management LLC now owns 38,904 shares of the medical technology company's stock valued at $357,000 after purchasing an additional 4,985 shares during the last quarter. First Eagle Investment Management LLC boosted its stake in Alphatec by 36.6% during the 4th quarter. First Eagle Investment Management LLC now owns 658,437 shares of the medical technology company's stock worth $6,044,000 after purchasing an additional 176,402 shares during the period. Commonwealth Equity Services LLC grew its position in Alphatec by 55.9% during the 4th quarter. Commonwealth Equity Services LLC now owns 36,929 shares of the medical technology company's stock worth $339,000 after purchasing an additional 13,246 shares during the last quarter. Finally, Swiss National Bank increased its stake in Alphatec by 1.1% in the fourth quarter. Swiss National Bank now owns 207,200 shares of the medical technology company's stock valued at $1,902,000 after purchasing an additional 2,300 shares during the period. Institutional investors and hedge funds own 66.35% of the company's stock.

Remove Ads

Insider Buying and Selling

In related news, COO Scott Lish sold 27,453 shares of the business's stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $11.49, for a total value of $315,434.97. Following the sale, the chief operating officer now directly owns 867,677 shares in the company, valued at $9,969,608.73. The trade was a 3.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP David Sponsel sold 58,283 shares of the firm's stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $10.71, for a total transaction of $624,210.93. Following the transaction, the executive vice president now owns 502,311 shares of the company's stock, valued at $5,379,750.81. This trade represents a 10.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 337,321 shares of company stock worth $3,828,060 in the last quarter. Company insiders own 22.80% of the company's stock.

Alphatec Price Performance

Alphatec stock traded down $0.06 during midday trading on Tuesday, reaching $10.08. The company's stock had a trading volume of 3,064,684 shares, compared to its average volume of 1,982,187. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. Alphatec Holdings, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $14.54. The firm has a market capitalization of $1.45 billion, a PE ratio of -7.88 and a beta of 1.39. The stock's 50 day simple moving average is $10.80 and its 200 day simple moving average is $9.08.

Alphatec (NASDAQ:ATEC - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The medical technology company reported ($0.23) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.04). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The company had revenue of $176.79 million for the quarter, compared to analysts' expectations of $172.74 million. On average, equities research analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Piper Sandler increased their target price on shares of Alphatec from $12.00 to $13.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. Needham & Company LLC reaffirmed a "buy" rating and set a $16.00 price objective on shares of Alphatec in a research report on Thursday, February 27th. HC Wainwright reissued a "buy" rating and issued a $20.00 target price on shares of Alphatec in a report on Tuesday, January 14th. StockNews.com upgraded Alphatec from a "sell" rating to a "hold" rating in a research note on Friday, February 28th. Finally, Barclays lifted their price objective on shares of Alphatec from $20.00 to $21.00 and gave the company an "overweight" rating in a research report on Wednesday, January 22nd. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, Alphatec presently has an average rating of "Moderate Buy" and a consensus price target of $17.67.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.